{"": [169, 1377, 0], "Introduction": [1378, 6240, 0], "Biophysical characterization": [6250, 7682, 0], "Alpha/B.1.1.7 establishes disease-causing infection at lower inoculation doses than original SARS-CoV-2 isolate": [7683, 9042, 0], "Determination of the evasion capacity of the N439K and N501Y variants in naturally induced antibody-mediated immunity": [9043, 10254, 0], "Determination of the evasion capacity of the RBD variants in vaccine-induced immunity": [10255, 11952, 0], "Results": [6241, 11952, 1], "Discussion": [11953, 19276, 0], "Production of recombinant SARS-CoV-2 RBD variants and human ACE-2 ectodomain": [19300, 20326, 0], "Protein stability determination": [20327, 20878, 0], "ACE-2/RBD affinity determination by BLI": [20879, 21670, 0], "ACE-2/RBD antibody inhibition assay": [21671, 23198, 0], "K18-hACE2 mouse COVID-19 model": [23199, 23817, 0], "RNA isolation and real-time PCR (qPCR)": [23818, 24681, 0], "SARS-CoV-2": [24682, 26930, 0], "Plaque reduction neutralization test": [26931, 28144, 0], "Blood samples": [28145, 28589, 0], "Biosafety": [28590, 28908, 0], "Statistics": [28909, 30304, 0], "Materials and methods": [19277, 30304, 1]}